About Us


Micro Labs

The well-planned and state-of-the-art facilities at Micro Labs have led to its accelerated growth in the pharmaceutical sector. Infrastructure plays a key role in the development and progress of a company.The reputation of our company is built on Manufacturing and R&D facilities that are designed to meet global standards, and stringent Quality standards that ensure we deliver only the best formulations and products.
Micro Labs has 14 state-of-the-art units that manufacture various pharmaceutical products. The manufacturing units are designed to meet the current global standards of GMP and safety standards for personnel.

The Company has globally certified GMP-compliant manufacturing facilities at the following locations:

3 sites in Hosur at Tamil Nadu – South India

7 sites in and around Bangalore – South India

1 site in Pondicherry – South India

1 site in Goa – Western India

1 site in Sikkim- North East India

These sites have the following international accreditations:

UK MHRA logo 4 sites approved by UK MHRA (MRP with other European Union member states)

Health Canada logo 2 sites approved by Health Canada

US-FDA-logo 4 sites approved US FDA

US-FDA-logo 2 sites & 2 are awiating for approval

API (Active Pharmaceutical Ingredient) site is designed to met European Union and US FDA standards

We have the unique distinction of being the only company in the country equipped with stand-alone, dedicated facilities that manufacture sensitive and potent pharmaceutical products. The leading regulatory agencies of the world- UK MRHA, MCC South Africa, Health Canada and US FDA have approved the facilities at Micro Labs. World-class manufacturing facilities coupled with a state-of-the-art R&D centre that manufactures innovative products, and ably supported by an intelligent Quality Management Systems implemented to perfection has taken Micro Labs to a commendable position in the domestic as well as global market.


  • Report adverse experiences with medications
  • Report serious adverse reactions. A reaction is serious when the patient outcome is:
    • Death
    • Life-threatening (real risk of dying)
    • Hospitalization (initial or prolonged)
    • Disability (significant, persistent or permanent)
    • Congenital anomaly
    • Required intervention to prevent permanent impairment or damage
  • Report even if:
    • You’re not certain the product caused adverse reaction
    • You don’t have all the details however point nos. 1, 5, 7, 8, 11, 15, 16 & 18 (see reverse) are essentially required.
  • Who can report:
    • Any health care professional (Doctors including Dentists, Nurses and Pharmacists).
  • Where to report:
    • After completing, please return this form to Micro Labs Ltd, Pharmacovigilance Cell
  • What happens to the submitted information:
    • Information provided in this form is handled in strict confidence. PV cell at Micro Labs will carry out causality analysis and the data is statistically analysed and finally submitted to CDSCO.


The patient’s identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the reporter’s identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction.